Trial · NCT00705679
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms | TFV Gel | 1024 | person-years | ||
| Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms | Placebo Gel | 1030 | person-years | ||
| Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms | TFV Gel | 61 | participants | ||
| Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms | Placebo Gel | 70 | participants | ||
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | Oral TDF | M184V mutation | 0 | participants | |
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | Oral TDF-FTC | M184V mutation | 1 | participants | |
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | Oral Placebo | M184V mutation | 0 | participants | |
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | TFV Gel | M184V mutation | 0 | participants | |
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | Gel Placebo | M184V mutation | 0 | participants | |
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | Oral TDF | No M184V mutation | 58 | participants | |
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | Oral TDF-FTC | No M184V mutation | 54 | participants | |
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | Oral Placebo | No M184V mutation | 60 | participants | |
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | TFV Gel | No M184V mutation | 60 | participants | |
| Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product | Gel Placebo | No M184V mutation | 68 | participants | |
| Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms | TFV Gel | 6.0 | 95% Confidence Interval 4.6 to 7.6 | cases per 100 person-years | |
| Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms | Placebo Gel | 6.8 | 95% Confidence Interval 5.3 to 8.6 | cases per 100 person-years | |
| Person-years of Follow-up of Oral TDF and Oral Placebo Arms | Oral TDF | 823 | person-years | ||
| Person-years of Follow-up of Oral TDF and Oral Placebo Arms | Oral Placebo | 838 | person-years | ||
| Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms | Oral TDF | 52 | participants | ||
| Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms | Oral Placebo | 35 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00705679/results